Skip to main content
TLRY
NASDAQ Life Sciences

Tilray Brands Issues 2.6M Shares to Extinguish $12M in Convertible Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.48
Mkt Cap
$538.813M
52W Low
$3.93
52W High
$23.2
52W Position info
14% above low
Off High info
81% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TLRY is trading near its 52-week low of $3.93 (14% above the low).

Summary

Tilray Brands exchanged $12 million of convertible debt for 2.64 million common shares, reducing debt but diluting existing shareholders.


Key Events · Financing and Capital Events · TLRY

  • Debt-for-Equity Exchange

    Tilray Brands issued 2,638,341 shares of common stock in exchange for $12 million aggregate principal amount of its 5.20% Convertible Senior Notes due June 15, 2027.

  • Share Dilution

    The issuance of 2.64 million new shares represents a notable dilutive event for existing shareholders, equivalent to approximately 2.2% of the company's market capitalization.

  • Debt Reduction

    The transaction successfully reduced the company's outstanding convertible debt by $12 million, improving its balance sheet.

  • Implied Share Price

    The shares were issued at an implied price of approximately $4.54 per share, which is slightly above the current market price of $4.48.


Analysis · TLRY · Life Sciences

Tilray Brands completed another series of private debt-for-equity exchanges, issuing 2.64 million common shares to eliminate $12 million in convertible senior notes. This move reduces the company's debt burden but results in significant dilution for existing shareholders, representing over 2% of the current market capitalization. This follows a pattern of similar debt-for-equity swaps by the company.

How filings like this one have moved

In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLRY was trading at $4.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $538.8M. The 52-week trading range was $3.93 to $23.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLRY - Latest Insights

TLRY
Sep 14, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.17
Real-time Price: $3.60 info
Change: -$0.570 (-14%) info
Market Cap: $533.493M info
TLRY
Aug 10, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.42
Real-time Price: $3.60 info
Change: -$0.8246 (-19%) info
Market Cap: $533.493M info
TLRY
Jul 28, 2026, 5:03 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $3.60 info
Change: -$0.490 (-12%) info
Market Cap: $533.493M info
TLRY
Jul 28, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $3.60 info
Change: -$0.485 (-12%) info
Market Cap: $533.493M info
TLRY
Jul 28, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $3.60 info
Change: -$0.4959 (-12%) info
Market Cap: $533.493M info